EpiCor’s ability to favorably shift CD4/CD8 cells suggests an application worth considering when dealing with a viral burden on the body. Is this correct?

A. Yes. The improved CD4/CD8 ratio is precisely what is desired for those dealing with a viral burden, as this ratio is often disrupted in this group.

There is no research specifically done in this area yet. However, it certainly seems as if EpiCor would be a tool worth strong consideration. More.

I cant really gove you an answer,but what I can give you is a way to a solution, that is you have to find the anglde that you relate to or peaks your interest. A good paper is one that people get drawn into because it reaches them ln some way.As for me WW11 to me, I think of the holocaust and the effect it had on the survivors, their families and those who stood by and did nothing until it was too late.